会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Jitter compensated numerically controlled oscillator
    • 抖动补偿数控振荡器
    • US08674777B1
    • 2014-03-18
    • US13615482
    • 2012-09-13
    • Robert MackTimothy Chen
    • Robert MackTimothy Chen
    • H03L1/00
    • G06F1/022G06F1/0328G06F1/08H03B28/00H03B2200/0088H03L1/00H03L7/0994
    • A method for compensating NCO jitter by changing a step value used to increment an accumulator in the NCO to make up for inaccuracies, or jitters. In one approach, a remainder in the accumulator may be monitored and a compensated clock close to the current edge of an ideal clock may be generated. In another approach, a compensated clock close to the next edge of the ideal clock may be generated after the current edge of the ideal clock is missed. The step value may be stored in a memory, which may be a register. A jitter compensator may include a comparator for monitoring the remainder in the accumulator or a detector for detecting whether an ideal clock has been missed. The jitter compensator may also change the step value to a step value for a faster clock to compensate jitter.
    • 一种用于通过改变用于增加NCO中的累加器的步长值来补偿NCO抖动以补偿不准确或不稳定的方法。 在一种方法中,可以监视累加器中的余数,并且可以产生接近理想时钟的当前边缘的补偿时钟。 在另一种方法中,在理想时钟的当前边缘被错过之后,可以产生靠近理想时钟的下一个边缘的补偿时钟。 步数值可以存储在可以是寄存器的存储器中。 抖动补偿器可以包括用于监视累加器中的余数的比较器或用于检测是否错过理想时钟的检测器。 抖动补偿器还可以将步长值改变为更快时钟的步进值以补偿抖动。
    • 10. 发明授权
    • Spiroazabicyclic heterocyclic compounds
    • 螺环双环杂环化合物
    • US6110914A
    • 2000-08-29
    • US171983
    • 1998-10-29
    • Eifion PhillipsRobert MackJohn MacorSimon Semus
    • Eifion PhillipsRobert MackJohn MacorSimon Semus
    • C07D491/22A61K20060101A61K31/395A61K31/435A61K31/4353A61K31/4355A61K31/436A61K31/4365A61K31/438A61K31/439A61K31/44A61K31/444A61K31/4738A61K31/4745A61K31/496A61K31/5377A61K31/695A61P20060101A61P1/00A61P1/04A61P25/00A61P25/04A61P25/14A61P25/16A61P25/18A61P25/22A61P25/24A61P25/28A61P25/34A61P43/00C07D20060101C07D491/12C07D491/20C07D495/12C07D499/21C07F5/02C07F7/18C07P499/21
    • C07D491/22
    • A compound of formula ##STR1## wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H.sub.2 or F.sub.2 ;A is N or C(R.sup.2); G is N or C(R.sup.3); D is N or C(R.sup.4);with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO;R.sup.1 is hydrogen or C.sub.1 to C.sub.4 alkyl;R.sup.2, R.sup.3, and R.sup.4 are independently hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, aryl, heteroaryl, OH, OC.sub.1 -C.sub.4 alkyl, CO.sub.2 R.sup.1, --CN, --NO.sub.2, --NR.sup.5 R.sup.6, --CF.sub.3, --OSO.sub.2 CF.sub.3 or R.sup.2 and R.sup.3, or R.sup.3 and R.sup.4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, aryl, heteroaryl, OH, OC.sub.1 -C.sub.4 alkyl, CO.sub.2 R.sup.1, --CN, --NO.sub.2, --NR.sup.5 R.sup.6, --CF.sub.3, --OSO.sub.2 CF.sub.3 ; R.sup.5 and R.sup.6 are independently hydrogen, C.sub.1 -C.sub.4 alkyl, C(O)R.sup.7, C(O)NHR.sup.8, C(O)OR.sup.9, SO.sub.2 R.sup.10 or may together be (CH.sub.2).sub.j Q(CH.sub.2).sub.k where Q is O, S, NR.sup.11, or a bond; j is 2 to 7, k is 0 to 2; R.sup.7, R.sup.8, R.sup.9, R.sup.10, and R.sup.11 are independently C.sub.1 -C.sub.4 alkyl, aryl, or heteroaryl, or an enantiomer thereof,and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.
    • PCT No.PCT / SE98 / 01364 Sec。 371日期:1998年10月29日第 102(e)1998年10月29日PCT PCT 1998年7月10日PCT公布。 公开号WO99 /​​ 03859 日期1999年1月28日其中n为0或1的下式化合物: m为0或1; p为0或1; X是氧或硫; Y是CH,N或NO; W是氧,H2或F2; A为N或C(R2); G为N或C(R3); D是N或C(R4); 条件是A,G和D中不超过一个为氮,但Y,A,G和D中的至少一个为氮或NO; R1是氢或C1-C4烷基; R2,R3和R4独立地是氢,卤素,C1-C4烷基,C2-C4烯基,C2-C4炔基,芳基,杂芳基,OH,OC1-C4烷基,CO2R1,-CN,-NO2,-NR5R6, CF 3,-OSO 2 CF 3或R 2,R 3或R 3和R 4分别可以一起形成分别含有0和2个氮原子之间的分别为A和G或G和D的六元芳族或杂芳族环,并被一个 C 1 -C 4烷基,C 2 -C 4烯基,C 2 -C 4炔基,芳基,杂芳基,OH,OC 1 -C 4烷基,CO 2 R 1,-CN,-NO 2,-NR 5 R 6 - CF 3,-OSO 2 CF 3; R 5和R 6独立地是氢,C 1 -C 4烷基,C(O)R 7,C(O)NHR 8,C(O)OR 9,SO 2 R 10或可以一起为(CH 2)j Q(CH 2) NR11,或债券; j为2〜7,k为0〜2; R 7,R 8,R 9,R 10和R 11独立地为C 1 -C 4烷基,芳基或杂芳基,或其对映异构体及其药学上可接受的盐,其制备方法,含有它们的组合物及其在治疗中的用途, 在治疗或预防精神病和智力障碍。